Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
4.070
-0.860 (-17.44%)
At close: Sep 12, 2025, 4:00 PM EDT
3.950
-0.120 (-2.95%)
After-hours: Sep 12, 2025, 7:59 PM EDT
Silexion Therapeutics Employees
As of December 31, 2024, Silexion Therapeutics had 14 total employees, including 11 full-time and 3 part-time employees.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,174,500
Market Cap
2.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLXN News
- 2 days ago - Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data - Benzinga
- 2 days ago - Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering - GlobeNewsWire
- 2 days ago - Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration - GlobeNewsWire
- 9 days ago - Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204 - GlobeNewsWire
- 11 days ago - Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference - GlobeNewsWire
- 4 weeks ago - Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds - GlobeNewsWire
- 6 weeks ago - Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation - GlobeNewsWire